1
|
Guerra-Rebollo M, Stampa M, Lázaro MÁ, Cascante A, Fornaguera C, Borrós S. Electrostatic Coating of Viral Particles for Gene Delivery Applications in Muscular Dystrophies: Influence of Size on Stability and Antibody Protection. J Neuromuscul Dis 2021; 8:815-825. [PMID: 34366365 DOI: 10.3233/jnd-210662] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
BACKGROUND Duchenne Muscular Dystrophy (DMD) is one of the most common muscular dystrophies, caused by mutated forms of the dystrophin gene. Currently, the only treatment available is symptoms management. Novel approximations are trying to treat these patients with gene therapy, namely, using viral vectors. However, these vectors can be recognized by the immune system decreasing their therapeutic activity and making impossible a multidose treatment due to the induction of the humoral immunity following the first dose. OBJECTIVE Our objective is to demonstrate the feasibility of using a hybrid vector to avoid immune clearance, based on the electrostatic coating of adeno-associated virus (AAVs) vectors with our proprietary polymers. METHODS We coated model adeno-associated virus vectors by electrostatic interaction of our cationic poly (beta aminoester) polymers with the viral anionic capsid and characterized biophysical properties. Once the nanoformulations were designed, we studied their in vivo biodistribution by bioluminescence analysis and we finally studied the capacity of the polymers as potential coatings to avoid antibody neutralization. RESULTS We tested two polymer combinations and we demonstrated the need for poly(ethylene glycol) addition to avoid vector aggregation after coating. In vivo biodistribution studies demonstrated that viral particles are located in the liver (short times) and also in muscles (long times), the target organ. However, we did not achieve complete antibody neutralization shielding using this electrostatic coating. CONCLUSIONS The null hypothesis stands: although it is feasible to coat viral particles by electrostatic interaction with a proprietary polymer, this strategy is not appropriate for AAVs due to their small size, so other alternatives are required as a novel treatment for DMD patients.
Collapse
Affiliation(s)
- Marta Guerra-Rebollo
- Grup d'Enginyeria de Materials (Gemat), Institut Químic de Sarriá (IQS), Universitat Ramon Llull (URL), Via Augusta, Barcelona, Spain.,Sagetis Biotech, Via Augusta, Barcelona, Spain
| | - María Stampa
- Grup d'Enginyeria de Materials (Gemat), Institut Químic de Sarriá (IQS), Universitat Ramon Llull (URL), Via Augusta, Barcelona, Spain
| | | | - Anna Cascante
- Grup d'Enginyeria de Materials (Gemat), Institut Químic de Sarriá (IQS), Universitat Ramon Llull (URL), Via Augusta, Barcelona, Spain.,Sagetis Biotech, Via Augusta, Barcelona, Spain
| | - Cristina Fornaguera
- Grup d'Enginyeria de Materials (Gemat), Institut Químic de Sarriá (IQS), Universitat Ramon Llull (URL), Via Augusta, Barcelona, Spain.,Sagetis Biotech, Via Augusta, Barcelona, Spain
| | - Salvador Borrós
- Grup d'Enginyeria de Materials (Gemat), Institut Químic de Sarriá (IQS), Universitat Ramon Llull (URL), Via Augusta, Barcelona, Spain.,Sagetis Biotech, Via Augusta, Barcelona, Spain
| |
Collapse
|
2
|
Brugada-Vilà P, Cascante A, Lázaro MÁ, Castells-Sala C, Fornaguera C, Rovira-Rigau M, Albertazzi L, Borros S, Fillat C. Oligopeptide-modified poly(beta-amino ester)s-coated AdNuPARmE1A: Boosting the efficacy of intravenously administered therapeutic adenoviruses. Theranostics 2020; 10:2744-2758. [PMID: 32194832 PMCID: PMC7052890 DOI: 10.7150/thno.40902] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2019] [Accepted: 12/23/2019] [Indexed: 01/09/2023] Open
Abstract
Oncolytic adenoviruses are used as agents for the treatment of cancer. However, their potential is limited due to the high seroprevalence of anti-adenovirus neutralizing antibodies (nAbs) within the population and the rapid liver sequestration when systemically administered. To overcome these challenges, we explored using nanoparticle formulation to boost the efficacy of systemic oncolytic adenovirus administration. Methods: Adenovirus were conjugated with PEGylated oligopeptide-modified poly(β-amino ester)s (OM-pBAEs). The resulting coated viral formulation was characterized in terms of surface charge, size, aggregation state and morphology and tested for anti-adenovirus nAbs evasion and activity in cancer cells. In vivo pharmacokinetics, biodistribution, tumor targeting, and immunogenicity studies were performed. The antitumor efficacy of the oncolytic adenovirus AdNuPARmE1A coated with OM-pBAEs (SAG101) in the presence of nAbs was evaluated in pancreatic ductal adenocarcinoma (PDAC) mouse models. Toxicity of the coated formulation was analyzed in vivo in immunocompetent mice. Results: OM-pBAEs conjugated to adenovirus and generated discrete nanoparticles with a neutral charge and an optimal size. The polymeric coating with the reporter AdGFPLuc (CPEG) showed enhanced transduction and evasion of antibody neutralization in vitro. Moreover, systemic intravenous administration of the formulation showed improved blood circulation and reduced liver sequestration, substantially avoiding activation of nAb production. OM-pBAEs coating of the oncolytic adenovirus AdNuPARmE1A (SAG101) improved its oncolytic activity in vitro and enhanced antitumor efficacy in PDAC mouse models. The coated formulation protected virions from neutralization by nAbs, as antitumor efficacy was preserved in their presence but was completely lost in mice that received the non-formulated AdNuPARmE1A. Finally, coated-AdNuPARmE1A showed reduced toxicity when high doses of the formulation were administered. Conclusions: The developed technology represents a promising improvement for future clinical cancer therapy using oncolytic adenoviruses.
Collapse
|
3
|
Fornaguera C, Guerra‐Rebollo M, Lázaro MÁ, Cascante A, Rubio N, Blanco J, Borrós S. In Vivo Retargeting of Poly(beta aminoester) (OM-PBAE) Nanoparticles is Influenced by Protein Corona. Adv Healthc Mater 2019; 8:e1900849. [PMID: 31478348 DOI: 10.1002/adhm.201900849] [Citation(s) in RCA: 28] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2019] [Revised: 07/28/2019] [Indexed: 12/29/2022]
Abstract
One of the main bottlenecks in the translation of nanomedicines from research to clinics is the difficulty in designing nanoparticles actively vectorized to the target tissue, a key parameter to ensure efficacy and safety. In this group, a library of poly(beta aminoester) polymers is developed, and it is demonstrated that adding specific combinations of terminal oligopeptides (OM-PBAE), in vitro transfection is cell selective. The current study aims to actively direct the nanoparticles to the liver by the addition of a targeting molecule. To achieve this objective, retinol, successfully attached to OM-PBAE, is selected as hepatic targeting moiety. It is demonstrated that organ biodistribution is tailored, achieving the desired liver accumulation. Regarding cell type transfection, antigen presenting cells in the liver are those showing the highest transfection. Thanks to proteomics studies, organ but not cellular biodistribution can be explained by the formation of differential protein coronas. Therefore, organ biodistribution is governed by differential protein corona formed when retinol is present, while cellular biodistribution is controlled by the end oligopeptides type. In summary, this work is a proof of concept that demonstrates the versatility of these OM-PBAE nanoparticles, in terms of the modification of the biodistribution of OM-PBAE nanoparticles adding active targeting moieties.
Collapse
Affiliation(s)
- Cristina Fornaguera
- Grup d'Enginyeria de Materials (Gemat)Institut Químic de Sarrià (IQS)Ramon Llull University (URL) Via Augusta 390 08017 Barcelona Spain
| | - Marta Guerra‐Rebollo
- Grup d'Enginyeria de Materials (Gemat)Institut Químic de Sarrià (IQS)Ramon Llull University (URL) Via Augusta 390 08017 Barcelona Spain
| | | | - Anna Cascante
- Sagetis‐Biotech SL Via Augusta 390 08017 Barcelona Spain
| | - Núria Rubio
- Grup de Terapia CellularInstitut de Química Avançada de Catalunya (IQAC‐CSIC) C/Jordi Girona 28‐26 08034 Barcelona Spain
| | - Jerónimo Blanco
- Grup de Terapia CellularInstitut de Química Avançada de Catalunya (IQAC‐CSIC) C/Jordi Girona 28‐26 08034 Barcelona Spain
| | - Salvador Borrós
- Grup d'Enginyeria de Materials (Gemat)Institut Químic de Sarrià (IQS)Ramon Llull University (URL) Via Augusta 390 08017 Barcelona Spain
- Sagetis‐Biotech SL Via Augusta 390 08017 Barcelona Spain
| |
Collapse
|
4
|
Fornaguera C, Guerra-Rebollo M, Ángel Lázaro M, Castells-Sala C, Meca-Cortés O, Ramos-Pérez V, Cascante A, Rubio N, Blanco J, Borrós S. APC Targeting: mRNA Delivery System for Targeting Antigen-Presenting Cells In Vivo (Adv. Healthcare Mater. 17/2018). Adv Healthc Mater 2018. [DOI: 10.1002/adhm.201870071] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- Cristina Fornaguera
- Sagetis Biotech SL; 08017 Barcelona Spain
- Grup d'Enginyeria de Materials (GEMAT); Institut Químic de Sarrià (IQS); Universitat Ramon Llull (URL); 08017 Barcelona Spain
| | - Marta Guerra-Rebollo
- CIBER of Biomaterials; Bioengineering and Nanomedicine (CIBER-BBN); 08034 Barcelona Spain
- Institute of Advanced Chemistry of Catalonia (IQAC-CSIC); 08034 Barcelona Spain
| | | | | | - Oscar Meca-Cortés
- CIBER of Biomaterials; Bioengineering and Nanomedicine (CIBER-BBN); 08034 Barcelona Spain
| | - Victor Ramos-Pérez
- Grup d'Enginyeria de Materials (GEMAT); Institut Químic de Sarrià (IQS); Universitat Ramon Llull (URL); 08017 Barcelona Spain
| | - Anna Cascante
- Sagetis Biotech SL; 08017 Barcelona Spain
- Grup d'Enginyeria de Materials (GEMAT); Institut Químic de Sarrià (IQS); Universitat Ramon Llull (URL); 08017 Barcelona Spain
| | - Núria Rubio
- CIBER of Biomaterials; Bioengineering and Nanomedicine (CIBER-BBN); 08034 Barcelona Spain
- Institute of Advanced Chemistry of Catalonia (IQAC-CSIC); 08034 Barcelona Spain
| | - Jerónimo Blanco
- CIBER of Biomaterials; Bioengineering and Nanomedicine (CIBER-BBN); 08034 Barcelona Spain
- Institute of Advanced Chemistry of Catalonia (IQAC-CSIC); 08034 Barcelona Spain
| | - Salvador Borrós
- Sagetis Biotech SL; 08017 Barcelona Spain
- Grup d'Enginyeria de Materials (GEMAT); Institut Químic de Sarrià (IQS); Universitat Ramon Llull (URL); 08017 Barcelona Spain
- CIBER of Biomaterials; Bioengineering and Nanomedicine (CIBER-BBN); 08034 Barcelona Spain
| |
Collapse
|
5
|
Fornaguera C, Guerra-Rebollo M, Ángel Lázaro M, Castells-Sala C, Meca-Cortés O, Ramos-Pérez V, Cascante A, Rubio N, Blanco J, Borrós S. mRNA Delivery System for Targeting Antigen-Presenting Cells In Vivo. Adv Healthc Mater 2018; 7:e1800335. [PMID: 29923337 DOI: 10.1002/adhm.201800335] [Citation(s) in RCA: 45] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2018] [Revised: 05/06/2018] [Indexed: 12/13/2022]
Abstract
The encapsulation of mRNA in nanosystems as gene vaccines for immunotherapy purposes has experienced an exponential increase in recent years. Despite the many advantages envisaged within these approaches, their application in clinical treatments is still limited due to safety issues. These issues can be attributed, in part, to liver accumulation of most of the designed nanosystems and to the inability to transfect immune cells after an intravenous administration. In this context, this study takes advantage of the known versatile properties of the oligopeptide end-modified poly (β-amino esters) (OM-PBAEs) to complex mRNA and form discrete nanoparticles. Importantly, it is demonstrated that the selection of the appropriate end-oligopeptide modifications enables the specific targeting and major transfection of antigen-presenting cells (APC) in vivo, after intravenous administration, thus enabling their use for immunotherapy strategies. Therefore, with this study, it can be confirmed that OM-PBAE are appropriate systems for the design of mRNA-based immunotherapy approaches aimed to in vivo transfect APCs and trigger immune responses to fight either tumors or infectious diseases.
Collapse
Affiliation(s)
- Cristina Fornaguera
- Sagetis Biotech SL; 08017 Barcelona Spain
- Grup d'Enginyeria de Materials (GEMAT); Institut Químic de Sarrià (IQS); Universitat Ramon Llull (URL); 08017 Barcelona Spain
| | - Marta Guerra-Rebollo
- CIBER of Biomaterials; Bioengineering and Nanomedicine (CIBER-BBN); 08034 Barcelona Spain
- Institute of Advanced Chemistry of Catalonia (IQAC-CSIC); 08034 Barcelona Spain
| | | | | | - Oscar Meca-Cortés
- CIBER of Biomaterials; Bioengineering and Nanomedicine (CIBER-BBN); 08034 Barcelona Spain
| | - Victor Ramos-Pérez
- Grup d'Enginyeria de Materials (GEMAT); Institut Químic de Sarrià (IQS); Universitat Ramon Llull (URL); 08017 Barcelona Spain
| | - Anna Cascante
- Sagetis Biotech SL; 08017 Barcelona Spain
- Grup d'Enginyeria de Materials (GEMAT); Institut Químic de Sarrià (IQS); Universitat Ramon Llull (URL); 08017 Barcelona Spain
| | - Núria Rubio
- CIBER of Biomaterials; Bioengineering and Nanomedicine (CIBER-BBN); 08034 Barcelona Spain
- Institute of Advanced Chemistry of Catalonia (IQAC-CSIC); 08034 Barcelona Spain
| | - Jerónimo Blanco
- CIBER of Biomaterials; Bioengineering and Nanomedicine (CIBER-BBN); 08034 Barcelona Spain
- Institute of Advanced Chemistry of Catalonia (IQAC-CSIC); 08034 Barcelona Spain
| | - Salvador Borrós
- Sagetis Biotech SL; 08017 Barcelona Spain
- Grup d'Enginyeria de Materials (GEMAT); Institut Químic de Sarrià (IQS); Universitat Ramon Llull (URL); 08017 Barcelona Spain
- CIBER of Biomaterials; Bioengineering and Nanomedicine (CIBER-BBN); 08034 Barcelona Spain
| |
Collapse
|
6
|
Fornaguera C, Lázaro MÁ, Brugada-Vilà P, Porcar I, Morera I, Guerra-Rebollo M, Garrido C, Rubio N, Blanco J, Cascante A, Borrós S. Application of an assay Cascade methodology for a deep preclinical characterization of polymeric nanoparticles as a treatment for gliomas. Drug Deliv 2018; 25:472-483. [PMID: 29412012 PMCID: PMC6058495 DOI: 10.1080/10717544.2018.1436099] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023] Open
Abstract
Glioblastoma multiforme (GBM) is the most devastating primary brain tumor due to its infiltrating and diffuse growth characteristics, a situation compounded by the lack of effective treatments. Currently, many efforts are being devoted to find novel formulations to treat this disease, specifically in the nanomedicine field. However, due to the lack of comprehensive characterization that leads to insufficient data on reproducibility, only a reduced number of nanomedicines have reached clinical phases. In this context, the aim of the present study was to use a cascade of assays that evaluate from physical-chemical and structural properties to biological characteristics, both in vitro and in vivo, and also to check the performance of nanoparticles for glioma therapy. An amphiphilic block copolymer, composed of polyester and poly(ethylene glycol; PEG) blocks, has been synthesized. Using a mixture of this copolymer and a polymer containing an active targeting moiety to the Blood Brain Barrier (BBB; Seq12 peptide), biocompatible and biodegradable polymeric nanoparticles have been prepared and extensively characterized. In vitro studies demonstrated that nanoparticles are safe for normal cells but cytotoxic for cancer cells. In vivo studies in mice demonstrated the ability of the Seq12 peptide to cross the BBB. Finally, in vivo efficacy studies using a human tumor model in SCID mice resulted in a significant 50% life-span increase, as compared with non-treated animals. Altogether, this assay cascade provided extensive pre-clinical characterization of our polymeric nanoparticles, now ready for clinical evaluation.
Collapse
Affiliation(s)
| | | | - Pau Brugada-Vilà
- a Sagetis-Biotech , Barcelona , Spain.,b Grup d'Enginyera de Materials (GEMAT) , Institut Químic de Sarrià, Universitat Ramon Llull , Barcelona , Spain
| | | | | | - Marta Guerra-Rebollo
- c Institut de Química Avançada de Catalunya (IQAC-CSIC) , Barcelona , Spain.,d Centro de Investigación Biomédica en Red en Bioingenierı´a , Biomateriales y Nanomedicina (CIBER-BBN) , Barcelona , Spain
| | - Cristina Garrido
- c Institut de Química Avançada de Catalunya (IQAC-CSIC) , Barcelona , Spain.,d Centro de Investigación Biomédica en Red en Bioingenierı´a , Biomateriales y Nanomedicina (CIBER-BBN) , Barcelona , Spain
| | - Núria Rubio
- c Institut de Química Avançada de Catalunya (IQAC-CSIC) , Barcelona , Spain.,d Centro de Investigación Biomédica en Red en Bioingenierı´a , Biomateriales y Nanomedicina (CIBER-BBN) , Barcelona , Spain
| | - Jerónimo Blanco
- c Institut de Química Avançada de Catalunya (IQAC-CSIC) , Barcelona , Spain.,d Centro de Investigación Biomédica en Red en Bioingenierı´a , Biomateriales y Nanomedicina (CIBER-BBN) , Barcelona , Spain
| | - Anna Cascante
- a Sagetis-Biotech , Barcelona , Spain.,b Grup d'Enginyera de Materials (GEMAT) , Institut Químic de Sarrià, Universitat Ramon Llull , Barcelona , Spain
| | - Salvador Borrós
- a Sagetis-Biotech , Barcelona , Spain.,b Grup d'Enginyera de Materials (GEMAT) , Institut Químic de Sarrià, Universitat Ramon Llull , Barcelona , Spain.,d Centro de Investigación Biomédica en Red en Bioingenierı´a , Biomateriales y Nanomedicina (CIBER-BBN) , Barcelona , Spain
| |
Collapse
|